BC-LI-0186 is a selective blocking agent (IC50=46.11nM) of the interaction between Leucyl-tRNA synthase (LRS, LeuRS) and RAS-related GTP-binding protein D(RagD), which competes with RagD. Binds to the LRS VC domain (KD=42.1nM), thereby inhibiting lysosomal localization of LRS and mTORC1 activity. It also effectively inhibits the activity of cancer-associated mTOR mutants and the growth of rapamycin resistant cancer cells.

 

Brand: BCM

 

Target: LeuRS and RagD interaction:42.1 nM(Kd), LeuRS and RagD interaction:46.11 nM

 

Boiling Point: 582.9±60.0 °C(Predicted)

 

Solubility: Soluble in DMSO.

 

pKa: 10.68±0.50(Predicted)

 

Isomeric SMILES: CC1=C(C(=O)N(N1C)C2=CC=C(C=C2)S(=O)(=O)NCCOC3=CC=CC=C3)C(C)C  

 

InChIKey: SQYWMHPZMHDCHP-UHFFFAOYSA-N  

 

InChI: InChI=1S/C22H27N3O4S/c1-16(2)21-17(3)24(4)25(22(21)26)18-10-12-20(13-11-18)30(27,28)23-14-15-29-19-8-6-5-7-9-19/h5-13,16,23H,14-15H2,1-4H3

 

Attribute
[Chem Name]	4-(2,3-dimethyl-5-oxo-4-propan-2-ylpyrazol-1-yl)-N-(2-phenoxyethyl)benzenesulfonamide
[Synonym]	BC-LI-0186
[CAS No.]	695207-56-8
[EINECS]	429.53
[MDL No.]	MFCD05259468
[Formula]	C22H27N3O4S
[Molecular]	429.53
[Form]	Solid Powder
[Storage]	Sealed in dry. Room Temperature

Goods Tag